JPMorgan raised the firm’s price target on BioMarin (BMRN) to $113 from $108 and keeps an Overweight rating on the shares. The firm adjusted the company’s model ahead of the Q2 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin’s BMN 349 Study: A New Frontier in Genetic Mutation Treatment
- BioMarin assumed with an Overweight at Morgan Stanley
- Positive Outlook for BioMarin Pharmaceutical Amid Competitive Challenges and Market Expansion Opportunities
- BioMarin Pharmaceutical’s Growth Potential and Competitive Edge Amidst Market Challenges
- BioMarin reports new data underscoring the long-term efficacy of ROCTAVIAN